Clearbridge Investments LLC Purchases New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS)

Clearbridge Investments LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 190,064 shares of the company's stock, valued at approximately $3,009,000. Clearbridge Investments LLC owned about 0.47% of Keros Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in KROS. AlphaQuest LLC increased its holdings in Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Keros Therapeutics during the fourth quarter valued at about $90,000. Exchange Traded Concepts LLC purchased a new position in Keros Therapeutics in the fourth quarter valued at about $99,000. China Universal Asset Management Co. Ltd. raised its holdings in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after purchasing an additional 1,372 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after buying an additional 1,100 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on KROS shares. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th. Wells Fargo & Company decreased their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Piper Sandler dropped their target price on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Friday, January 17th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Finally, Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $42.33.

Remove Ads

Keros Therapeutics Stock Down 0.3 %

Shares of NASDAQ:KROS traded down $0.03 during midday trading on Tuesday, reaching $9.95. The company's stock had a trading volume of 283,631 shares, compared to its average volume of 1,299,463. The stock has a fifty day moving average of $10.97 and a 200 day moving average of $32.35. Keros Therapeutics, Inc. has a twelve month low of $9.37 and a twelve month high of $72.37. The firm has a market capitalization of $403.59 million, a PE ratio of -1.91 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.